生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Tazemetostat (EPZ-6438) is a potent, selective, and orally available EZH2 inhibitor. It inhibits human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM and inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat also inhibits rat EZH2 with an IC50 of 4 nM and inhibits EZH1 with an IC50 of 392 nM. It induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells [1]. | ||
作用机制 | EPZ-6438 inhibits EZH2 in a manner competitive with the substrate S-adenosylmethionine (SAM) binding to EZH2. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human HeLa cells | Function assay | 72 h | Inhibition of EZH2 in human HeLa cells assessed as reduction in H3K27me3 levels incubated for 72 hrs by ELISA method, IC50=0.02 μM. | 26189078 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.75mL 0.35mL 0.17mL |
8.73mL 1.75mL 0.87mL |
17.46mL 3.49mL 1.75mL |
参考文献 |
---|